Current medical and surgical management of Raynaud's syndrome

    Research output: Contribution to journalArticle

    23 Citations (Scopus)

    Abstract

    Raynaud's syndrome (RS) is characterized by episodic digital ischemia induced by cold or emotional stress. Pathophysiologic mechanisms include temporary vasospasm and fixed digital artery obstruction. A number of pharmacologic and invasive therapies have been studied to treat RS symptoms; however, there are no specific treatments that are currently approved by the U.S. Food and Drug Administration specifically for RS. Of the available pharmacologic agents, calciumchannel blockers remain the preferred initial treatment for vasospastic RS, although many vasodilators have been studied and found to be efficacious. Vasodilators are less effective in treating digital artery obstruction, and no treatments have been found to be universally beneficial, although the phosphodiesterase V inhibitors have been gaining in popularity. Invasive therapies may have a role in selective cases. In this review, the current evidence of treatment for RS is summarized.

    Original languageEnglish (US)
    Pages (from-to)1710-1716
    Number of pages7
    JournalJournal of Vascular Surgery
    Volume57
    Issue number6
    DOIs
    StatePublished - Jun 2013

    Fingerprint

    Vasodilator Agents
    Therapeutics
    Arteries
    Type 5 Cyclic Nucleotide Phosphodiesterases
    Cold Ischemia
    Phosphodiesterase Inhibitors
    United States Food and Drug Administration
    Psychological Stress

    ASJC Scopus subject areas

    • Cardiology and Cardiovascular Medicine
    • Surgery

    Cite this

    Current medical and surgical management of Raynaud's syndrome. / Landry, Gregory.

    In: Journal of Vascular Surgery, Vol. 57, No. 6, 06.2013, p. 1710-1716.

    Research output: Contribution to journalArticle

    @article{06552ab1dfb6468f8ef83d9bc4e1fd71,
    title = "Current medical and surgical management of Raynaud's syndrome",
    abstract = "Raynaud's syndrome (RS) is characterized by episodic digital ischemia induced by cold or emotional stress. Pathophysiologic mechanisms include temporary vasospasm and fixed digital artery obstruction. A number of pharmacologic and invasive therapies have been studied to treat RS symptoms; however, there are no specific treatments that are currently approved by the U.S. Food and Drug Administration specifically for RS. Of the available pharmacologic agents, calciumchannel blockers remain the preferred initial treatment for vasospastic RS, although many vasodilators have been studied and found to be efficacious. Vasodilators are less effective in treating digital artery obstruction, and no treatments have been found to be universally beneficial, although the phosphodiesterase V inhibitors have been gaining in popularity. Invasive therapies may have a role in selective cases. In this review, the current evidence of treatment for RS is summarized.",
    author = "Gregory Landry",
    year = "2013",
    month = "6",
    doi = "10.1016/j.jvs.2013.03.012",
    language = "English (US)",
    volume = "57",
    pages = "1710--1716",
    journal = "Journal of Vascular Surgery",
    issn = "0741-5214",
    publisher = "Mosby Inc.",
    number = "6",

    }

    TY - JOUR

    T1 - Current medical and surgical management of Raynaud's syndrome

    AU - Landry, Gregory

    PY - 2013/6

    Y1 - 2013/6

    N2 - Raynaud's syndrome (RS) is characterized by episodic digital ischemia induced by cold or emotional stress. Pathophysiologic mechanisms include temporary vasospasm and fixed digital artery obstruction. A number of pharmacologic and invasive therapies have been studied to treat RS symptoms; however, there are no specific treatments that are currently approved by the U.S. Food and Drug Administration specifically for RS. Of the available pharmacologic agents, calciumchannel blockers remain the preferred initial treatment for vasospastic RS, although many vasodilators have been studied and found to be efficacious. Vasodilators are less effective in treating digital artery obstruction, and no treatments have been found to be universally beneficial, although the phosphodiesterase V inhibitors have been gaining in popularity. Invasive therapies may have a role in selective cases. In this review, the current evidence of treatment for RS is summarized.

    AB - Raynaud's syndrome (RS) is characterized by episodic digital ischemia induced by cold or emotional stress. Pathophysiologic mechanisms include temporary vasospasm and fixed digital artery obstruction. A number of pharmacologic and invasive therapies have been studied to treat RS symptoms; however, there are no specific treatments that are currently approved by the U.S. Food and Drug Administration specifically for RS. Of the available pharmacologic agents, calciumchannel blockers remain the preferred initial treatment for vasospastic RS, although many vasodilators have been studied and found to be efficacious. Vasodilators are less effective in treating digital artery obstruction, and no treatments have been found to be universally beneficial, although the phosphodiesterase V inhibitors have been gaining in popularity. Invasive therapies may have a role in selective cases. In this review, the current evidence of treatment for RS is summarized.

    UR - http://www.scopus.com/inward/record.url?scp=84880836467&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=84880836467&partnerID=8YFLogxK

    U2 - 10.1016/j.jvs.2013.03.012

    DO - 10.1016/j.jvs.2013.03.012

    M3 - Article

    C2 - 23618525

    AN - SCOPUS:84880836467

    VL - 57

    SP - 1710

    EP - 1716

    JO - Journal of Vascular Surgery

    JF - Journal of Vascular Surgery

    SN - 0741-5214

    IS - 6

    ER -